TABLE: Sage IPO spices up sour biotech market
This article was originally published in Scrip
Executive Summary
Sage Therapeutics closed its first day as a public company on 18 July at $30.10 per share, which was 67.2% above its $18 initial public offering price, but it ended the week with a much different experience than other biotechnology companies.